SAB Biotherapeutics Inc.

SABS | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.39

-$0.12 (-3.42%)

At close: Sep 21, 2026, 4:00 PM ET

$3.44

+$0.05 (+1.47%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-3.42%

(1D)

Rating

Updated: Aug 14, 2026

33.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $308.44M

1D Range

3.39 3.54

52W Range

1.85 5.15

Valuation (TTM)

PE -3.94

PB 1.44

EV/EBITDA -22.29

Valuation (NTM)

Forward PE N/A

Forward PEG -0.03

Price Target $11.33

Cash Flow

FCF Yield -23.6%

SBC Adj. FCF Yield -30.5%

SBC Impact -29.3%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -144.1% | -88.4%

Dil EPS 3Y | 5Y 72.1% | 23.6%

FCF 3Y | 5Y -37.3% | -32.5%

Returns

ROA -5.4%

ROE -6.7%

ROIC -31.6%

Financial Health

Net Cash

$97.5M

Current Ratio 9.22

Interest Coverage -310.26

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious dis...

Sector Healthcare

Industry Biotechnology

Employees 86

IPO Date Feb 8, 2021

Website www.sab.bio

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 13, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$11

Upside

+224.48%

Buy (4)

Hold (0)

Sell (0)

Analyst Details ➞